<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762293</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-IIb-CRC</org_study_id>
    <nct_id>NCT01762293</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib in Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and&#xD;
      Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study&#xD;
      has shown that the toxicity is manageable.&#xD;
&#xD;
      The purpose of this study is to determine whether Famitinib can improve progression free&#xD;
      survival compared with placebo in patients with advanced colorectal cancer who failed in&#xD;
      previous at least two lines of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>42-day cycle visit until disease progress</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>body vitals, laboratory parameters</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Colorectal Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <description>Famitinib 25 mg p.o. qd</description>
    <arm_group_label>Famitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>p.o. qd</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologic confirmed recurrent and/or metastatic CRC and previously&#xD;
             received at least two lines of standard therapy failure(must include 5-Fu,irinotecan&#xD;
             and oxaliplatin)&#xD;
&#xD;
          -  At least one measurable lesion, larger than 10 mm in diameter by spiral CT&#xD;
             scan(scanning layer ≤ 5 mm )&#xD;
&#xD;
          -  age ≥ 18 and ≤ 70&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  More than 4 weeks after operation, chemotherapy, radiotherapy, cytotoxic agents or&#xD;
             tyrosine kinase inhibitors&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Before or at the same time any, second malignancies except cured basal cell carcinoma&#xD;
             of skin and carcinoma in-situ of uterine cervix&#xD;
&#xD;
          -  Prior therapy with tyrosine kinase -inhibitor agent targeting at VEGFR, PDGFR and&#xD;
             c-Kit(e.g sorafenib,sunitinib,regorafenib)&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration&#xD;
&#xD;
          -  Having obvious gastrointestinal hemorrhagic tendency&#xD;
&#xD;
          -  Known Spinal Cord compression or diseases of brain or pia mater by CT /MRI screening&#xD;
&#xD;
          -  Organ tumor overloading&#xD;
&#xD;
          -  Inadequate hepatic, renal, heart, and hematologic functions (hemoglobin ≤ 90g/L,&#xD;
             platelets ≤ 100×10^9/L, neutrophils ≤ 1.5×10^9/L, total bilirubin ≥ 1.25×the upper&#xD;
             limit of normal(ULN), and serum transaminase ≥ 1.5×ULN (If liver metastases, serum&#xD;
             transaminase≥ 2.5×ULN), creatinine clearance rate ≤ 60ml/min, cholesterol ≥ 1.5×ULN&#xD;
             and triglyceride≥ 2.5 x ULN, LVEF: &lt; 50%&#xD;
&#xD;
          -  Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite using&#xD;
             single medical therapy, more than cla ss I (NCI CTCAE 3.0 ) myocardial ischemia,&#xD;
             arrhythmia, or cardiac insufficiency&#xD;
&#xD;
          -  urinary protein≥ ++ or 24-hour urinary protein ≥ 1.0 g&#xD;
&#xD;
          -  Long-term untreated wounds or fractures&#xD;
&#xD;
          -  Blood coagulation abnormal, having hemorrhagic tendency&#xD;
&#xD;
          -  Within 1 year before the first treatment occurs artery / venous thromboembolic events,&#xD;
             such as cerebral vascular accident (including transient ischemic attack), deep vein&#xD;
             thrombosis and pulmonary embolism, etc.&#xD;
&#xD;
          -  Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or&#xD;
             its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5,&#xD;
             with the purpose of prevention, the use of small doses of warfarin (1mg orally, once&#xD;
             daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed&#xD;
&#xD;
          -  Female: All subjects who are not surgically sterile or postmenopausal must agree and&#xD;
             commit to the use of a reliable method of birth control for the duration of the study&#xD;
             and for 6 months after the last dose of test article. Child bearing potential, a&#xD;
             negative urine or serum pregnancy test result before initiating Famitinib. Male: All&#xD;
             subjects who are not surgically sterile or postmenopausal must agree and commit to the&#xD;
             use of a reliable method of birth control for the duration of the study and for 6&#xD;
             months after the last dose of test article.&#xD;
&#xD;
          -  Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot&#xD;
             maintain in the normal range&#xD;
&#xD;
          -  Abuse of psychiatric drugs or dysphrenia&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial&#xD;
&#xD;
          -  Ascites need treatment&#xD;
&#xD;
          -  Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital&#xD;
             immunodeficiency, or organ transplantation&#xD;
&#xD;
          -  Evidence of significant medical illness that in the investigator's judgment will&#xD;
             substantially increase the risk associated with the subject's participation in and&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Lin, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital, Peking University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruihua Xu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Sun Yet-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer center, Sun Yet-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital, Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC</keyword>
  <keyword>Famitinib</keyword>
  <keyword>Phase II</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

